Table 2.

Treatment and prognosis of patients.

Patient ID	Age(years)	Sex	Antibody titer	Affected eyes	Therapeutic methods	BCVA at diagnosis	Last follow-up BCVA
A1	71	Female	AQP4-IgG:>80u/ml	Right	IVMP and oral prednisolone	3.5	3.5
A2	45	Female	AQP4-IgG:10.37u/ml	Left	Oral prednisolone	1.7	2
A3	11	Female	AQP4-IgG:67.90u/ml	Right	IVMP and oral prednisolone	2	0.4
A4	43	Female	AQP4-IgG:40.83u/ml	Right	None	0.6	0
A5	32	Female	AQP4-IgG:>80u/ml	Right	IVMP and oral prednisolone	2.5	0.2
A6	25	Female	AQP4-IgG:26.8u/ml	Left	IVMP and oral prednisolone	2.5	0.4
M1	18	Male	MOG-IgG:1:10	Left	IVMP and oral prednisolone	0.4	0.2
M2	32	Female	MOG-IgG:1:10	Left	IVMP and oral prednisolone	0.5	0.1
M3	57	Female	MOG-IgG:1:10	Left	IVMP and oral prednisolone	1.1	0.4
M4	24	Female	MOG-IgG:1:100	Left	IVMP and oral prednisolone	1.1	0.2
M5	39	Female	MOG-IgG:1:10	Right	IVMP and oral prednisolone	2	0
M6	70	Female	MOG-IgG:1:100	Left	IVMP and oral prednisolone	2	0.1
M7	35	Male	MOG-IgG:1:32	Right	IVMP and oral prednisolone	2	0.9
M8	31	Male	MOG-IgG:1:100	Right	IVMP and oral prednisolone	0.5	0.2

Age: years at diagnosis; IVMP, intravenous pulses of methylprednisolone. BCVA: Snellen visual acuity was converted to logarithm of the minimum angle of resolution (logMAR). Counting fingers vision was converted to a value of 2.0 logMAR, hand motion vision was converted to a value of 2.5 logMAR, light perception vision was converted to a value of 3.0 logMAR and no light perception vision was converted to a value of 3.5 logMAR.